The grant will fund a collaboration investigating whether genomic signatures and other biomarkers can be used in clinical diagnosis and monitoring of kidney cancer.
Investigators intend to genotype the biorepository using Illumina arrays with the aim of identifying markers that can be used to inform treatment and prevention efforts.
The program will provide two young scientists with funding for independent research as well as resources to help them commercialize their technology.
Researchers hope to identify exosomal biomarkers that can predict or detect cancer recurrence and metastasis at its earliest stages.
The firm said that the test may be validated as a prognostic test for colorectal cancer and a predictive test for cancer immunotherapies.
The researchers believe that by monitoring mtDNA copy number in blood, they will be able to identify people at risk for developing CHD who could benefit from preventative efforts.
The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.
OncoDNA has launched two new precision cancer medicine projects, the budgets for which total €16 million and are being supported in part by the Belgian Walloon Region.
A $900,000 grant will support a partnership between Christiana Care and Jerusalem-based biotech firm NovellusDx on genome editing technologies.
UT-SWMC researcher Eric Olson will study dystrophin produced with CRISPR/Cas9 genome editing in a mouse model, as well as off-target effects.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.